However, an analysis based on the cBioPortal database collected 1441 pieces of data from 1441 metastatic NSCLC patients and showed no prognostic value of disruptive or non-disruptive mutation of TP53 (41). This evidence concerns the gene TP53 and non-small cell lung carcinoma.